Iron Chelation Therapy Market Report 2026

The iron chelation therapy market size has grown strongly in recent years. It will grow from $2.68 billion in 2025 to $2.86 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of transfusion-dependent anemias, wider availability of chelation drugs, expansion of pediatric hematology services, improved survival of thalassemia patients, growing clinical awareness of iron overload risks.

The iron chelation therapy market size is expected to see strong growth in the next few years. It will grow to $3.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing adoption of patient-centric treatment regimens, rising development of next-generation chelators, expansion of home-based iron management, growing focus on reducing therapy side effects, increasing investments in rare disease therapeutics. Major trends in the forecast period include increasing preference for oral chelation therapies, rising focus on patient adherence and compliance, growing use of personalized iron management plans, expansion of long-term iron overload monitoring, enhanced development of modified-release formulations.

The increasing number of blood transfusions is expected to drive the growth of the iron chelation therapy market in the coming years. Blood transfusion involves administering donated blood to a patient to restore blood volume or address specific health conditions, such as anemia or blood loss. The rise in blood transfusions is primarily driven by the growing prevalence of complex surgical procedures, which often result in significant blood loss, necessitating transfusions to maintain hemodynamic stability and support recovery. Iron chelation therapy is employed to remove excess iron that accumulates in the body due to frequent transfusions. For example, according to the American Red Cross, a US-based non-profit organization, approximately 16 million blood components are transfused annually in the U.S. Sickle cell disease affects 90,000 to 100,000 individuals, with about 1,000 babies born with the condition each year, and many patients require lifelong blood transfusions. Therefore, the increasing number of blood transfusions is driving the growth of the iron chelation therapy market.

Major companies operating in the iron chelation therapy market are concentrating on developing next-generation chelators with improved bioavailability to enhance treatment efficacy, reduce adverse effects, and boost patient adherence. Next-generation chelators with enhanced bioavailability are designed to optimize absorption and therapeutic effectiveness, allowing for more convenient dosing schedules and better compliance in managing iron overload disorders. For instance, in March 2023, Chiesi Farmaceutici S.p.A., an Italy-based pharmaceutical company, received approval from Health Canada for FERRIPROX MR, a twice-daily extended-release iron chelator for treating iron overload in patients with thalassemia, sickle cell disease, and other anemias. This formulation provides improved convenience and continued support for rare disease management, with clinical data demonstrating that FERRIPROX MR 1,000 mg is both effective and safe, maintaining an acceptable safety profile for patients with iron overload.

In September 2024, Mitem Pharma, a France-based pharmaceutical company, acquired worldwide rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed amount. Through this acquisition, Mitem Pharma aims to strengthen its presence in the iron chelation therapy market and expand its portfolio with a well-established treatment for iron overload disorders. Novartis AG is a Switzerland-based pharmaceutical company that provides iron chelation therapy.

Major companies operating in the iron chelation therapy market are Novartis AG, Bayer AG, Vifor Pharma Group, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Cipla Ltd., Zydus Cadila, Natco Pharma Ltd., Apotex Inc., Mylan NV (Viatris Inc.), Chiesi Farmaceutici S.pA., Lupin Limited, Taro Pharmaceutical Industries Ltd., Unichem Laboratories Ltd., Accord Healthcare, Sandoz International GmbH, Recordati S.p.A., Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Keryx Biopharmaceuticals Inc.

North America was the largest region in the iron chelation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iron chelation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the iron chelation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the iron chelation therapy market by increasing costs of imported chelating agents, active pharmaceutical ingredients, formulation excipients, and infusion-related medical supplies. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported branded chelation drugs, while Asia-Pacific faces cost pressures on generic drug manufacturing. These tariffs are increasing treatment costs and influencing drug pricing strategies. However, they are also encouraging domestic pharmaceutical production, regional sourcing of raw materials, and increased development of locally manufactured iron chelation therapies.

The iron chelation therapy market research report is one of a series of new reports that provides iron chelation therapy market statistics, including iron chelation therapy industry global market size, regional shares, competitors with a iron chelation therapy market share, detailed iron chelation therapy market segments, market trends and opportunities, and any further data you may need to thrive in the iron chelation therapy industry. This iron chelation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Iron chelation therapy refers to a medical treatment aimed at removing excess iron from the body in patients with conditions requiring frequent blood transfusions or those with iron overload disorders. This therapy uses chelating agents that bind to excess iron, enabling its excretion through urine or feces. It is employed in managing thalassemia, sickle cell disease, and other chronic anemias to prevent organ damage and improve long-term patient outcomes.

The primary types of iron chelation therapy include deferasirox, deferoxamine, and deferiprone. Deferasirox is an oral chelating agent commonly used to remove excess iron in patients undergoing frequent blood transfusions due to conditions such as beta-thalassemia and other chronic anemias. The therapy can be administered via oral, parenteral, intravenous, and subcutaneous routes. Key indications include thalassemia, sickle cell disease, myelodysplastic syndromes (MDS), and non-transfusion-dependent thalassemia (NTDT). It is suitable for a wide patient population, including pediatric, adult, elderly, and gender-specific groups, and is used by various end users such as hospitals, specialty clinics, homecare settings, and others.

The iron chelation therapy market includes revenues earned by entities by providing services such as clinical trial management, personalized treatment planning, drug development, and monitoring iron levels. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron chelation therapy market also includes sales of injectable iron chelators, extended-release formulations, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.